The report "Artificial Intelligence in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) - Global Forecast to 2028", is projected to reach USD 4.9 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 40.2% during the forecast period.
Browse 150 market data Tables and 50 Figures spread through 200 Pages and in-depth TOC on "Artificial Intelligence in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) - Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html
The ascent of precision medicine, characterized by tailored treatments aligned with individual patient attributes, has become a pivotal trend. This paradigm shift has bestowed prominence upon the field. Leveraging AI algorithms, intricate genetic and molecular datasets can be deciphered, discerning patient subgroups that exhibit heightened potential for favorable responses to specific therapies. This, in turn, culminates in the formulation of treatments that are both targeted and notably efficacious, ultimately propelling the growth of the AI in drug discovery market. The introduction of novel AI-driven methodologies necessitates regulatory bodies to undergo adaptation, a process that could potentially engender delays or uncertainties. These dynamics, in turn, pose potential challenges and threats to the market landscape.
“Services segment is expected to grow at the highest rate during the forecast period.”
Based on offering, the AI in drug discovery market is bifurcated into software and services. In 2022, the services segment is poised to register the highest CAGR throughout the forecast period. The ascendancy of AI services is attributed to their instrumental role in conducting comprehensive analysis and interpretation of intricate biological and chemical data. Leveraging advanced machine learning algorithms, these services enable the extraction of meaningful insights from expansive datasets, thereby facilitating the identification of potential drug candidates and more precise prognostication of their behaviors. These determinants collectively propel the dynamic expansion of this market segment.
“Machine learning technology segment accounted for the largest share of the global AI in drug discovery market.”
Based on technology, AI in drug discovery market is bifurcated into machine learning, natural language processing (NLP), context-aware processing or context-aware computing and other technologies. In 2022, the machine learning sector held the largest market share and is poised to achieve the highest CAGR throughout the projected timeframe. Within the machine learning technology sphere, there exists further segmentation, encompassing deep learning, supervised learning, reinforcement learning, unsupervised learning, and other machine learning technologies. Machine learning algorithms have consistently showcased exceptional adeptness in dissecting intricate and multifaceted datasets, spanning genomics, proteomics, chemical structures, and clinical data. Their capacity to identify latent patterns and correlations within the data, which might elude conventional methodologies, empowers researchers to predict potential drug interactions, efficacy profiles, and safety attributes with heightened precision.
“The neurology diseases therapeutic area segment is expected to grow at the highest CAGR of the AI in drug discovery market in 2022.”
Based on therapeutic area, the AI in drug discovery market encompasses neurodegenerative diseases, oncology, cardiovascular diseases, metabolic diseases, immunology, and other distinct therapeutic areas. Notably, the neurology segment is expected to grow at the highest CAGR during the forecast period. This projection stems from AI's pivotal role in resolving the intricacies associated with neurological drug development. Additionally, strategic partnerships between pharmaceutical entities and solution providers significantly contribute to the elevated growth rate observed within the neurodegenerative diseases segment.
“North America is expected to dominate the AI in drug discovery market in 2022”
In 2022, North America commanded the foremost position in the global AI in drug discovery market share and is poised to maintain this leadership with the highest anticipated CAGR during the forecast period. This commanding position is attributed to North America's robust technological underpinning, which serves as a fundamental bedrock for the seamless integration and implementation of AI technologies within the domain of drug discovery. Distinguished by its advanced IT infrastructure, North America adeptly manages the intricate handling, processing, and analysis of the voluminous and intricate datasets intrinsic to drug discovery procedures. Undeniably, this region has spearheaded the early adoption of AI technology in drug discovery and developmental pursuits. This leadership is underpinned by a nexus of crucial factors, including the presence of key industry players, a firmly established pharmaceutical and biotechnology sector, substantial investments in research and development, and a steadfast focus on advancing innovative solutions. The culmination of these elements decisively contributes to North America's commanding market presence and is indicative of the region's sustained and remarkable growth trajectory in the AI in drug discovery domain.
The prominent players in artificial intelligence (AI) in drug discovery market are NVIDIA Corporation (US), Exscientia (UK), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft Corporation (US), Google (US), Atomwise Inc. (US), Illumina, Inc. (US), NuMedii, Inc. (US), XtalPi Inc. (US), Iktos (France), Tempus Labs (US), Deep Genomics, Inc. (Canada), Verge Genomics (US), BenchSci (Canada), Insitro (US), Valo Health (US), BPGbio, Inc. (US), IQVIA Inc (US), Labcorp (US), Tencent Holdings Limited (China), Predictive Oncology, Inc. (US), Celsius Therapeutics (US), CytoReason (Israel), Owkin, Inc. (US), Cloud Pharmaceuticals (US), Evaxion Biotech (Denmark), Standigm (South Korea), BIOAGE (US), Envisagenics (US), and Aria Pharmaceuticals, Inc. (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441